FDA Chaos and Foreign Price Controls Are Collapsing American Innovation cover art

FDA Chaos and Foreign Price Controls Are Collapsing American Innovation

FDA Chaos and Foreign Price Controls Are Collapsing American Innovation

Listen for free

View show details

About this listen

 FDA reversals and price controls are handing biotech dominance to China. We expose the national security crisis in drug development.

The FDA is facing a crisis of confidence that threatens the stability of the entire US biopharmaceutical industry. In this episode, John Stanford is joined by Jef Akst, Managing Editor at BioSpace, to expose how recent "regulatory reversals" and inconsistent decision-making are rendering major vaccine and therapeutic programs "uninvestable". We analyze the shocking "Moderna gate" incident, where the FDA issued a "refuse to file" letter for an mRNA flu vaccine only to reverse course days later, a chaotic move that sent stock prices flying and disrupted timelines for the entire vaccine sector.

Beyond the FDA, a new national security threat is emerging in the form of "Most Favored Nation" (MFN) pricing proposals. We unveil data from the Incubate MFN Tracker, which catalogs how these European-style price controls are now being flagged in quarterly SEC filings (10-Ks and 10-Qs) as material risks to business operations. Companies large and small are warning that MFN policies will compress expected returns and force a reprioritization away from riskier, high-impact R&D. This creates a vacuum that allows adversaries like China to further develop their own pipelines and grow a stronger foothold in the global market.

This episode also covers the shifting center of gravity in clinical research. While 58% of industry professionals still choose the US as the best place to start a career, 27% now look to Asia-Pacific, while only 9% choose Europe—a stark warning of what happens when regions adopt restrictive pricing policies. We discuss Senator Bill Cassidy’s new "Patient and Families First" white paper, which proposes solutions like an Australia-style pilot for faster Phase 1 trials and updated pathways for digital health and AI tools.

Finally, we look ahead to the State of the Union, where polling reveals that only 2% of Americans believe Congress should prioritize lowering drug costs, with the vast majority focused on grocery and insurance affordability instead.

Join the Conversation
Does the current FDA instability make you worry about the future of new medicines reaching patients? Do you believe importing foreign price controls is worth the risk of losing American biotech leadership to China?
Should Congress focus on insurance reform instead of drug price caps to help with affordability?
Drop your thoughts in the comments below

If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true

Link to articles
https://endpoints.news/pharma-is-done-negotiating-as-trump-pushes-to-codify-deals/ https://www.biospace.com/business/opinion-2026-could-mark-a-turning-point-for-american-innovation https://endpoints.news/even-europeans-dont-see-a-future-in-euro-biopharma-anymore/

Timestamps
0:00 Making Medicine disclaimer, no medical advice and no investment advice
0:42 Making Medicine Press Pass with BioSpace Managing Editor Jeff Akst
1:16 What BioSpace covers, biotech news, drug development, VC funding, FDA approvals
3:42 Is the FDA functioning properly, transparency and communication problems
4:17 FDA reversals and the Moderna mRNA flu vaccine refuse to file letter
6:19 Ripple effects, Moderna stock, vaccine timelines, and mRNA platform investment risk
8:37 FDA shifting to stricter approvals, risk benefit changes, and trial design uncertainty
10:35 Drug development timelines, regulatory instability, and investor confidence
12:17 Inside FDA culture, leadership turnover, layoffs, and decision making uncertainty
12:50 National priority vouchers, review delays, and why companies hesitate to apply
16:11 Psychedelics for depression and Alzheimer’s drug development with tau targeting
26:13 State of the Union, drug pricing politics, insurance reform, and voter affordability priorities

DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
No reviews yet